Short answer
10x Genomics, Inc. (TXG) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
10x Genomics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Detailed revenue, earnings, guidance and operating metrics contained in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $150.7M, up 1%, with consumables growth offsetting instrument weakness
- Gross margin 75% vs 67%, aided by lower inventory write-downs and favorable product mix
- Operating loss narrowed to $16.1M from $32.2M, while net loss improved to $19.4M from $27.5M
- Atera commercial shipments began, adding a potential growth driver across discovery, translational and biopharma research
- 2026 revenue guidance raised to $625M-$635M from $610M-$630M, with liquidity of $575.7M in cash and securities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 10x Genomics, Inc. 8-K filings
Get the next TXG 8-K as it lands
Follow TXG for push alerts, or ask the research agent what this filing means.